The Prognostic Value of Lymph Node Involvement after Neoadjuvant Chemotherapy Is Different among Breast Cancer Subtypes.
Lucie LaotEnora LaasNoemie GirardElise DumasEric DaoudBeatriz GrandalJean-Yves PiergaFlorence CoussyYoulia KirovaElsy El-AlamGuillaume BataillonMarick LaeFlorence LlouquetFabien ReyalAnne-Sophie HamyPublished in: Cancers (2021)
The prognostic value of residual axillary disease should be considered differently in the 3 BC subtypes to accurately stratify patients with a high risk of recurrence after NAC who should be offered second line therapies.